- Home
- SDA vs ELDN Comparison
SDA vs ELDN Comparison
Compare SDA & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDA | ELDN |
|---|---|---|
| Founded | 2007 | 2004 |
| Country | China | United States |
| Employees | 560 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.0M | 208.6M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | SDA | ELDN |
|---|---|---|
| Price | $1.81 | $2.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $4.75 | ★ $8.50 |
| AVG Volume (30 Days) | 538.9K | ★ 913.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.27 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.87 | N/A |
| Revenue Next Year | $12.21 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.54 | $1.35 |
| 52 Week High | $4.98 | $4.60 |
Technical Indicators
Market Signals| Indicator | SDA | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 41.01 | 57.17 |
| Support Level | $1.77 | $2.48 |
| Resistance Level | $2.18 | $2.77 |
| Average True Range (ATR) | 0.23 | 0.21 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 7.14 | 43.85 |
Price Performance
Historical ComparisonAbout SDA SunCar Technology Group Inc.
SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.